30 products | 23 new records + 7 supplemented records

Renal findings at a glance

Start with the action, then check the limitation. Each panel is tied to one identified primary source, not a merged recommendation. Open the full quick answer for tables, exact product scope, units, dates, RX evidence and existing source differences.

No patient dose is calculated. Selected renal passages are not complete monographs or independent clinical approval. No-adjustment guidance does not eliminate monitoring; PK findings do not establish a dialysis regimen.

Current v7.3 updates | Renal measure and dialysis checkpoints | Source-integrity findings

New exact-product record

Irinotecan liposome - ONIVYDE IV infusion

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

This source only - not a merged recommendation

What matters first

Product: Adult IV ONIVYDE liposomal irinotecan; not conventional irinotecan and not interchangeable dose-for-dose.

Renal action / finding: Mild/moderate PK finding only; no new dose derived.
Evidence or dialysis limit: CrCl <30: insufficient data; dialysis schedule not established.
Monitoring / application: Confirm the liposomal formulation and exact combination regimen.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Renal categories; severe defined as CrCl <30 mL/min in selected PK text

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Lazertinib - LAZCLUZE tablets

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult oral LAZCLUZE with amivantamab in the labeled lung-cancer regimen; partner-drug guidance is separate.

Renal action / finding: eGFR 30-89: no renal adjustment.
Evidence or dialysis limit: eGFR <30, including ESRD: not studied.
Monitoring / application: Review amivantamab and the complete regimen independently.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: eGFR 30-89 mL/min as printed; supporting PK uses CKD-EPI

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Levacetylleucine - AQNEURSA oral suspension

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

This source only - not a merged recommendation

What matters first

Product: AQNEURSA oral suspension for labeled Niemann-Pick disease type C neurological manifestations; apply product age/weight eligibility separately.

Renal action / finding: Renal effect unknown; do not infer no adjustment.
Evidence or dialysis limit: No numerical renal or dialysis regimen established in this passage.
Monitoring / application: Confirm product eligibility and obtain specialist guidance for the unresolved renal question.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: No renal adjustment method established in selected PK text

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

Supplemented existing record

Milnacipran (Savella)

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult oral SAVELLA for fibromyalgia; not levomilnacipran extended-release.

Renal action / finding: CrCl 5-29: maintenance 25 mg twice daily; response-dependent increase to 50 mg twice daily.
Evidence or dialysis limit: ESRD: not recommended. Mild: no adjustment; moderate: caution.
Monitoring / application: Do not skip titration or abruptly stop extended treatment.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Estimated CrCl, mL/min; severe 5-29

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Mirikizumab - OMVOH (IV induction / SC maintenance)

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

This source only - not a merged recommendation

What matters first

Product: Adult OMVOH in its labeled IBD regimen. IV induction and subcutaneous maintenance require their own product and dose instructions; this page summarizes renal PK only.

Renal action / finding: CrCl 30-89: PK observation, not a new dose algorithm.
Evidence or dialysis limit: Selected text supplies no severe-renal or dialysis regimen.
Monitoring / application: Identify indication, IV induction versus SC maintenance, and presentation.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Cockcroft-Gault CrCl 30-89 mL/min in population PK

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Mirvetuximab soravtansine - ELAHERE IV infusion

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult IV ELAHERE for labeled biomarker-selected ovarian/fallopian/peritoneal cancer; renal guidance does not replace adjusted-ideal-body-weight dosing.

Renal action / finding: CrCl 30-89: no renal adjustment.
Evidence or dialysis limit: CrCl 15 to <30 and ESRD: effects unknown; dialysis dosing not established.
Monitoring / application: Confirm dosing-weight method and ocular safety requirements.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: CrCl, mL/min; use section 8.6 category boundaries

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Niraparib/abiraterone acetate - AKEEGA tablets

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

This source only - not a merged recommendation

What matters first

Product: Adult oral fixed-combination AKEEGA with the required accompanying regimen; not niraparib or abiraterone single-agent guidance.

Renal action / finding: Mild/moderate: no modification; severe: monitor and modify for toxicity.
Evidence or dialysis limit: No numeric severe-renal or dialysis regimen established here.
Monitoring / application: Use the fixed-combination toxicity instructions and required accompanying therapy.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Renal impairment categories in section 8.7; supporting component PK does not validate the fixed combination in dialysis

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

Supplemented existing record

Omadacycline (Nuzyra)

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult NUZYRA IV and oral products for their labeled infections; the usual route-specific loading and administration instructions remain necessary.

Renal action / finding: No renal adjustment, including ESRD receiving hemodialysis.
Evidence or dialysis limit: Do not infer a CRRT schedule or interchangeable oral/IV loading.
Monitoring / application: Review oral fasting and cation-separation instructions.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Qualitative renal categories, including ESRD on hemodialysis

Source revision: 05/2026
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Opicapone - ONGENTYS capsules

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

This source only - not a merged recommendation

What matters first

Product: Adult oral ONGENTYS as adjunct to levodopa/carbidopa; renal instruction does not replace the full Parkinson regimen review.

Renal action / finding: No adjustment in mild/moderate/severe impairment; avoid ESRD.
Evidence or dialysis limit: CrCl <15: avoid. Do not infer a dialysis regimen.
Monitoring / application: Severe impairment: monitor adverse effects and stop for intolerance.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: CrCl, mL/min; ESRD avoidance below 15

Source revision: 11/2025
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Repotrectinib - AUGTYRO capsules

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This source only - not a merged recommendation

What matters first

Product: AUGTYRO oral capsules for the labeled molecularly selected oncology indication and age group; not a full oncology regimen.

Renal action / finding: Mild/moderate impairment: no modification under section 8.6.
Evidence or dialysis limit: eGFR <30 or dialysis: recommended dose not established.
Monitoring / application: Use the full indication, interactions and toxicity-modification instructions.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: eGFR, mL/min as printed in section 8.6

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

Supplemented existing record

Rimegepant orally disintegrating tablets (Nurtec ODT)

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

This source only - not a merged recommendation

What matters first

Product: Adult NURTEC ODT for its labeled migraine uses; an orally disintegrating tablet, not an intranasal CGRP product.

Renal action / finding: No renal adjustment above the ESRD restriction.
Evidence or dialysis limit: CrCl <15: avoid; ESRD and dialysis not studied.
Monitoring / application: Check indication-specific frequency and interacting drugs.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: CrCl, mL/min; ESRD avoidance below 15

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Ritlecitinib - LITFULO capsules

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

This source only - not a merged recommendation

What matters first

Product: LITFULO oral capsules for labeled severe alopecia areata in adults and adolescents >=12 years; PK-only renal summary.

Renal action / finding: PK-only: severe-renal exposure rise was not considered clinically significant.
Evidence or dialysis limit: ESRD and renal-transplant recipients not studied.
Monitoring / application: Do not turn a PK observation into a dialysis or transplant regimen.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: MDRD eGFR, mL/min as printed in PK text

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

What this roundup does not complete

Thirty previously uncovered RX URLs now have selected summaries; five other attempted pages did not yield usable renal text. All 26 A-Z letters still require complete linked-monograph review. The separate historical drug archive was not used.

Counts and remaining-work estimate | v7.2 scope and limitations